April 8th, 2020

Click here to begin reading
your complementary article

Comparison of Outcomes in Patients with Early-stage Mucinous Endometrial Cancer and Those with Endometrioid Endometrial Cancer, With and Without Adjuvant Therapy
Authors:  Sharon Owusu-Darko, M.D., J. Alejandro Rauh-Hain, M.D., Neil S. Horowitz, M.D., Annekathryn Goodman, M.D., John O. Schorge, M.D., and Marcela G. del Carmen, M.D., M.P.H.
  OBJECTIVE: To compare risk factors, treatment, and outcomes in patients with stage I/II mucinous endometrial cancer (MEC) relative to those of patients with endometrioid endometrial cancer (EEC).

STUDY DESIGN: We conducted a case-control study of patients with MEC and EEC. Patients with stage IA, IB, or II MEC treated at the 2 institutions between 01/01/ 1996 and 01/01/2007 were identified. Each MEC case was matched with 2 EEC controls by age, stage, grade, and year of diagnosis. The Kaplan-Meier method was used to generate overall survival (OS) data. Factors predictive of outcome were compared using the log-rank test and Cox proportional hazards model.

RESULTS: A total of 34 patients with MEC were compared to 68 controls with EEC. All patients were treated by hysterectomy and bilateral salpingo-oophorectomy. Use of adjuvant radiation therapy was similar between cases and controls. The 5-year disease-free survival (DFS) rates were not significantly different in patients with MEC when compared to those with EEC (89% vs. 92%, respectively, p=0.2). The 5-year OS rates for patients with MEC and the control group were 95% and 96%, respectively (p=0.1).

CONCLUSION: Patients with early-stage MEC and EEC have similar DFS and overall survival.
Keywords:  endometrial cancer, endometrioid endometrial cancer, gynecological malignancies, hyperestrogenism, mucinous endometrial cancer
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from